Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial

What Was Tested

The paper reports a study of NPH Insulin (isophane), published as a randomized controlled trial.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

In a controlled multicenter and open-label trial, the researchers randomly assigned patients with DKA to receive intravenous treatment with regular or glulisine insulin until resolution of DKA.

After resolution of ketoacidosis, patients treated with intravenous regular insulin were transitioned to subcutaneous NPH and regular insulin twice daily (n = 34).

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

The participants were allocated by chance, so the NPH Insulin (isophane) group and the comparison group should start out alike.

Everyone knew when NPH Insulin (isophane) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

More than one site took part, so the participants came from several places.

Patients treated with intravenous glulisine insulin were transitioned to subcutaneous glargine once daily and glulisine before meals (n = 34).

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetic Ketoacidosis, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin, Isophane and Patient Compliance.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of NPH Insulin (isophane).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (Diabetes care), a journal based in United States.

More context: the NPH Insulin (isophane) compound page.